MSB
Mesoblast Ltd
$2.03
▼ -1.46%
Market cap
$2.64B
Turnover
$4,819,676
Last price
$2.03
Day change
-1.46%
Announcements
13
Range, past year
Open 2.760 · Low 1.527 · Now 2.030 · High 3.310
Open MSB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
MSB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
25/100
Wyckoff phase
Accumulation1d
Trend stage
Neutral
1 Day
-1.5%
1 Week
+3.3%
1 Month
-4.2%
1 Year
-28.0%
RSI
44
Avg daily range
4.2%
Mesoblast Ltd scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -22.9%
- Risk rating: High
- Composite downside risk elevated
MSB announcements
Recent price-sensitive releases.
- 2026-09-24 FDA Approves New Potency Assay for Commercial Ryoncil Progress Report
- 2026-08-27 MSB Annual Financial Results and Operational Update Web Cast | Preliminary Final Report
- 2026-08-27 Annual Financial Results Presentation Company Presentation | Preliminary Final Report
- 2026-08-27 Preliminary Final Report including Appendix 4E Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement
- 2026-08-17 Major Milestone Treatment Completed in P3 Trial for CLBP Progress Report
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-14 Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
More Health Care stocks
Most traded in the same sector.